TR201901045T4 - İnsan TLR2 ve insan TLR4'e bağlanan yeni bispesifik antikor. - Google Patents

İnsan TLR2 ve insan TLR4'e bağlanan yeni bispesifik antikor. Download PDF

Info

Publication number
TR201901045T4
TR201901045T4 TR2019/01045T TR201901045T TR201901045T4 TR 201901045 T4 TR201901045 T4 TR 201901045T4 TR 2019/01045 T TR2019/01045 T TR 2019/01045T TR 201901045 T TR201901045 T TR 201901045T TR 201901045 T4 TR201901045 T4 TR 201901045T4
Authority
TR
Turkey
Prior art keywords
human
tlr2
tlr4
antibody
seq
Prior art date
Application number
TR2019/01045T
Other languages
English (en)
Inventor
Takeuchi Satoshi
Sato Masahito
Suzuki Jotarou
SOGA Shinji
Takasaki Jun
Aoyama Koji
Okuyama Chie
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of TR201901045T4 publication Critical patent/TR201901045T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

[Problem] İnsan TLR2 ve insan TLR4 aracılı immün inflamatuar etkileri inhibe etmek amacıyla hem insan TLR2 hem de insan TLR4 üzerinde aktivite göstermek suretiyle bir immün inflamatuar hastalığı önlemek veya tedavi etmek için bir bispesifik antikor sağlamak. [Çözüm için Araçlar] SEQ ID NO:4'ün 1 ila 120 numaralı amino asitlerini içeren amino asit dizisinden meydana gelen bir anti-insan TLR2 antikorunun bir ağır zincir değişken bölgesini; SEQ ID NO:6'nın 1 ila 113 numaralı amino asitlerini içeren amino asit dizisinden meydana gelen bir anti-insan TLR2 antikorunun bir hafif zincir değişken bölgesini; SEQ ID NO:4'ün 491 ila 609 numaralı amino asitlerini içeren amino asit dizisinden meydana gelen bir anti-insan TLR4 antikorunun bir ağır zincir değişken bölgesini; ve SEQ ID NO:4'ün 625 ila 732 numaralı amino asitlerini içeren amino asit dizisinden meydana gelen bir anti-insan TLR4 antikorunun bir hafif zincir bölgesini içeren, insan TLR2 ve insan TLR4 için bir bispesifik antikor sağlanmaktadır.
TR2019/01045T 2014-02-28 2015-02-27 İnsan TLR2 ve insan TLR4'e bağlanan yeni bispesifik antikor. TR201901045T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014038438 2014-02-28

Publications (1)

Publication Number Publication Date
TR201901045T4 true TR201901045T4 (tr) 2019-02-21

Family

ID=54009171

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01045T TR201901045T4 (tr) 2014-02-28 2015-02-27 İnsan TLR2 ve insan TLR4'e bağlanan yeni bispesifik antikor.

Country Status (14)

Country Link
US (1) US10253105B2 (tr)
EP (1) EP3112462B1 (tr)
JP (1) JP6579097B2 (tr)
KR (1) KR20160125965A (tr)
CN (1) CN106062193B (tr)
BR (1) BR112016019929A2 (tr)
CA (1) CA2941014A1 (tr)
ES (1) ES2709996T3 (tr)
MX (1) MX2016011228A (tr)
PL (1) PL3112462T3 (tr)
PT (1) PT3112462T (tr)
RU (1) RU2016134913A (tr)
TR (1) TR201901045T4 (tr)
WO (1) WO2015129858A1 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048971A1 (fr) * 2016-03-15 2017-09-22 Univ Rabelais Francois Constructions peptidiques bispecifiques et leur utilisation dans le traitement de maladies notamment imflammatoires
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
JP7773133B2 (ja) * 2020-07-08 2025-11-19 学校法人常翔学園 炎症性疾患治療剤
KR102790119B1 (ko) * 2023-05-09 2025-04-08 주식회사 뉴라메디 항 tlr2 항체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
JP4263953B2 (ja) 2003-06-23 2009-05-13 三洋電機株式会社 半導体装置及びその製造方法
JP3810388B2 (ja) 2003-07-14 2006-08-16 株式会社中央精機 両頭側面フライス盤
US7388080B2 (en) 2003-08-20 2008-06-17 University Of Massachusetts Selective inhibition of toll-like receptor-2
ATE510853T1 (de) 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
AU2003300896A1 (en) * 2003-12-10 2005-07-14 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
EP1711531B9 (en) 2003-12-10 2012-07-25 Novimmune SA Neutralizing anti tlr4/md-2 antibodies and methods of use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
AU2005325482B2 (en) * 2004-12-10 2011-06-16 Novimmune S.A. Combining therapies targeting multiple toll-like receptors and use thereof
CN103382222B (zh) * 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
BRPI1014449A2 (pt) * 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
KR102057742B1 (ko) * 2011-11-17 2019-12-19 군드람 정 의학적 용도를 위한 이중특이성 항체
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
EP2831117B1 (en) 2012-03-29 2017-11-01 NovImmune SA Anti-tlr4 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3112462B1 (en) 2018-12-05
PL3112462T3 (pl) 2019-06-28
CN106062193A (zh) 2016-10-26
EP3112462A1 (en) 2017-01-04
RU2016134913A (ru) 2018-03-30
JPWO2015129858A1 (ja) 2017-03-30
ES2709996T3 (es) 2019-04-22
US10253105B2 (en) 2019-04-09
EP3112462A4 (en) 2017-11-01
WO2015129858A1 (ja) 2015-09-03
US20160355602A1 (en) 2016-12-08
KR20160125965A (ko) 2016-11-01
CA2941014A1 (en) 2015-09-03
JP6579097B2 (ja) 2019-09-25
BR112016019929A2 (pt) 2017-10-17
MX2016011228A (es) 2016-11-30
PT3112462T (pt) 2019-02-08
CN106062193B (zh) 2020-08-25

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
MY181106A (en) Anti-lag3 antibodies and uses thereof
SA519400924B1 (ar) بروتينات ثنائية النوعية وطرق لتحضيرها
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201791393A2 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
PE20150002A1 (es) Anticuerpos anti-fcrn
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MY166776A (en) Humanised anti-ctla4 antibodies
WO2011113019A3 (en) Ctla4 proteins and their uses
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
MA40182A (fr) NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
EA201490433A1 (ru) Новое антитело против ngf человека
EA201400447A1 (ru) АНТИТЕЛА К CD1d
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
MY185114A (en) Improved il-6 antibodies